Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D at all. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. — Allergy, 2018 Jul — 73(7):1393-1414. — doi: 10.1111/all.13397.
Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ at all. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. — Allergy, 2011 Mar — 66(3):317-30. — doi:10.1111/j.1398-9995.2010.02496.x.
Silpa-archa N, Kulthanan K, Pinkaew S. Physical urticaria: prevalence, type and natural course in a tropical country. — J Eur Acad Dermatol Venereol, 2011 Oct — 25(10):1194-9. — doi:10.1111/j.1468-3083.2010.03951.x.
Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H at all. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. — Allergy, 2017 Dec — 72(12):2005-2016. — doi:10.1111/all.13209.
Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. — Clin Exp Allergy, 2009 Jun — 39(6):777-87. — doi:10.1111/j.1365-2222.2009.03256.x.
Sabine Altrichter, Hans-Jürgen Peter, Dina Pisarevskaja, Martin Metz, Peter Martus and Marcus Maurer. IgE Mediated Autoallergy against Thyroid Peroxidase — A Novel Pathomechanism of Chronic Spontaneous Urticaria? PLoS One, 2011 — 6(4): e14794. — doi:10.1371/journal.pone.0014794
Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. — J Allergy Clin Immunol, 2010 Feb — 125(2 Suppl 2):S73-80. — doi:10.1016/j.jaci.2009.11.017.
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E at all. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. — J Invest Dermatol, 2015 Jan — 135(1):67-75. — doi:10.1038/jid.2014.306.
Marcus Maurer, M.D., Karin Rosén, M.D., Ph.D., Hsin-Ju Hsieh, Ph.D., Sarbjit Saini, M.D., Clive Grattan at all. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. — N Engl J Med 2013—368:924-935. — doi:10.1056/NEJMoa1215372
Kaplan A1, Ledford D, Ashby M, Canvin J, Zazzali JL at all. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. — J Allergy Clin Immunol, 2013 Jul — 132(1):101-9. — doi:10.1016/j.jaci.2013.05.013.
Casale TB, Bernstein JA, Maurer M, Saini SS, Trzaskoma B at all. Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy. — J Allergy Clin Immunol Pract, 2015 Sep-Oct — 3(5):743-50.e1. — doi:10.1016/j.jaip.2015.04.015.
Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. — Pharmacology & Therapeutics, 01 Oct 2002, 96(1):23-43. — doi:10.1016/S0163-7258(02)00297-8.
nih.gov
ncbi.nlm.nih.gov
O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. — Br J Dermatol, 1997 Feb — 136(2):197-201. — PMID 9068731.
